Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 12, 2007

View Archived Issues

Pharmacokinetics of GSK-221149A studied to prepare for clinical trial

C-reactive protein, neopterin correlate with PRTX-100 dose in healthy subjects

Antiinflammatory effects of the GABA-B agonist baclofen shown in mice

Recent Abbott patents describe new ACC inhibitors

Novel chemokine CCR5 receptor antagonists emerge from Roche R&D

Recent Bayer patent describes new agents for thromboembolic disorders

Alpharma obtains U.S. rights to Diractin from IDEA

Power3 Medical Products reports preliminary results of international validation study of PD test

Iomai begins phase I/II trial of immunostimulant patch with H5N1 influenza vaccine

Series C financing to fund Trophos' TRO-19622 and TRO-40303

Update on Pozen and AstraZeneca's PN-400 program

NeuroSearch begins phase II study of ABT-894 for neuropathic pain

Spectrum begins enrolling patients in second pivotal phase III trial of EOquin

OSI Prosidion reports results from metformin and PSN-9301 interaction study

IL-22 blockade shows benefit in mouse model of rheumatoid arthritis

Positive first-in-human trial results of novel endothelin antagonist from Actelion

Lilly launches Cialis for erectile dysfunction in Japan

Innogenetics to discontinue investment in candidate HCV E1 vaccine

Affymetrix enters into licensing agreement with Empire Genomics

Penwest and Otsuka enter into R&D agreement

FDA approves Adventrx clinical development plan for ANX-514

XTL Biopharmaceuticals begins phase IIb trial of bicifadine for diabetic neuropathic pain

Enrollment begins for CeNeS and Ergomed's phase II trial of CNS-5161 for cancer pain

Moberg Derma initiates enrollment of phase III trial of K-101 for onychomycosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...